Literature DB >> 10898702

Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci.

F Guerin1, E Varon, A B Hoï, L Gutmann, I Podglajen.   

Abstract

Oropharyngeal samples from 60 hospitalized patients (30 fluoroquinolone [FQ]-treated and 30 non-FQ-treated patients) and 30 untreated nonhospitalized healthy control subjects yielded 20 isolates of viridans group streptococci with reduced susceptibility to FQ, mostly from the hospitalized patients. An efflux phenotype was commonly encountered, expressed either alone or with topoisomerase mutations. Interspecies transfer of the efflux phenotype was demonstrated via transformation of Streptococcus pneumoniae R6 with DNA from S. mitis and S. oralis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10898702      PMCID: PMC90040          DOI: 10.1128/AAC.44.8.2197-2200.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong.

Authors:  P L Ho; T L Que; D N Tsang; T K Ng; K H Chow; W H Seto
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  M J Gill; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Molecular characterization of the gene encoding the DNA gyrase A subunit of Streptococcus pneumoniae.

Authors:  D Balas; E Fernández-Moreira; A G De La Campa
Journal:  J Bacteriol       Date:  1998-06       Impact factor: 3.490

4.  Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.

Authors:  V Zeller; C Janoir; M D Kitzis; L Gutmann; N J Moreau
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

5.  Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.

Authors:  B Fournier; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

6.  High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

Authors:  C Janoir; V Zeller; M D Kitzis; N J Moreau; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

7.  Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.

Authors:  I González; M Georgiou; F Alcaide; D Balas; J Liñares; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

8.  DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.

Authors:  N P Brenwald; M J Gill; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.

Authors:  E Varon; C Janoir; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more
  7 in total

1.  Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  D J Bast; J C de Azavedo; T Y Tam; L Kilburn; C Duncan; L A Mandell; R J Davidson; D E Low
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

2.  Prophylactic treatment of anthrax with antibiotics.

Authors:  C A Hart; N J Beeching
Journal:  BMJ       Date:  2001-11-03

3.  Independent behavior of commensal flora for carriage of fluoroquinolone-resistant bacteria in patients at admission.

Authors:  Victoire de Lastours; Françoise Chau; Florence Tubach; Blandine Pasquet; Etienne Ruppé; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

4.  Fluoroquinolone resistance in Streptococcus dysgalactiae subsp. equisimilis and evidence for a shared global gene pool with Streptococcus pyogenes.

Authors:  M D Pinho; J Melo-Cristino; M Ramirez
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

5.  In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.

Authors:  Patrick Grohs; Serge Houssaye; Agnès Aubert; Laurent Gutmann; Emmanuelle Varon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

6.  Fluoroquinolone resistance in atypical pneumococci and oral streptococci: evidence of horizontal gene transfer of fluoroquinolone resistance determinants from Streptococcus pneumoniae.

Authors:  Margaret Ip; Shirley S L Chau; Fang Chi; Julian Tang; Paul K Chan
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191

7.  Evolution of the capsular gene locus of Streptococcus pneumoniae serogroup 6.

Authors:  P E Bratcher; I H Park; M B Oliver; M Hortal; R Camilli; S K Hollingshead; T Camou; M H Nahm
Journal:  Microbiology (Reading)       Date:  2010-10-07       Impact factor: 2.777

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.